TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01960309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimal invasive cardiac imaging
Description: * Coronary CT angiography (CCTA)~* Coronary magnetic resonance imaging (CMR)~* Echocardiography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimal invasive cardiac imaging
Description: * Coronary CT angiography (CCTA)~* Coronary magnetic resonance imaging (CMR)~* Echocardiography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimal invasive cardiac imaging
Description: * Coronary CT angiography (CCTA)~* Coronary magnetic resonance imaging (CMR)~* Echocardiography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimal invasive cardiac imaging
Description: * Coronary CT angiography (CCTA)~* Coronary magnetic resonance imaging (CMR)~* Echocardiography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimal invasive cardiac imaging
Description: * Coronary CT angiography (CCTA)~* Coronary magnetic resonance imaging (CMR)~* Echocardiography

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minimal invasive cardiac imaging
Description: * Coronary CT angiography (CCTA)~* Coronary magnetic resonance imaging (CMR)~* Echocardiography
Study: NCT03404739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Solution
Description: These patients will be given only one dose of ceftazidime at the start of POEM plus 2 doses of saline solution every 12 hours after the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftazidime
Description: These patients will be given ceftazidime 2g at the start of POEM plus additional 2 doses given every 12 hours after the procedure.
Study: NCT00682474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling Intervention
Description: Four 30-minute individual student-centered smoking cessation counseling intervention sessions delivered by school nurses to adolescent smokers in grades 9-12

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Intervention
Description: Attention-control comparison condition consisting of four individual sessions with the school nurse to check smoking status and deliver a series of standardized pamphlets on smoking and cessation to adolescent smokers in grades 9-12
Study: NCT02742883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with diffuse intrinsic pontine glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT03790371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: vaginal misoprostol prior IUD insertion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: vaginal placebo tablet prior IUD insertion
Study: NCT02208089

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transepithelial Photorefractive Keratectomy (TransPRK)
Description: Aberrometry or topography guided transepithelial photorefractive keratectomy (TransPRK) using the Schwind Amaris 750s excimer laser (www.eye-tech-solutions.com), an 8mm treatment diameter, and a tissue saving algorithm targeting selected higher order aberrations only. TransPRK will be followed immediately by corneal collagen cross-linking (CXL).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal Collagen Cross-Linking (CXL)
Description: Riboflavin soak: 10 minutes total soak time; application of 0.1% riboflavin preparation (VibeX Rapid - www.avedro.com) each 2 minutes with gentle balanced salt solution irrigation to remove excess riboflavin prior to UV light exposure.~UV light exposure: Total treatment time 8 minutes (370nm wavelength; 30mW/cm2 irradiance; 4 minutes total UV exposure time, pulsed 1.5 seconds on 1.5 seconds off; Avedro KXL I light source)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal Collagen Cross-Linking (CXL)
Description: Riboflavin soak: 10 minutes total soak time; application of 0.1% riboflavin preparation (VibeX Rapid - www.avedro.com) each 2 minutes with gentle balanced salt solution irrigation to remove excess riboflavin prior to UV light exposure.~UV light exposure: Total treatment time 8 minutes (370nm wavelength; 30mW/cm2 irradiance; 4 minutes total UV exposure time, pulsed 1.5 seconds on 1.5 seconds off; Avedro KXL I light source)
Study: NCT05186792

Intervention type: OTHER
Intervention: Test:mycoplasma
Description: Retrospective analysis of records of recruits to a previous mycoplasma study.
Study: NCT02132806

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezosurgery with biomaterial mp3 + bracket

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezosurgery with biomaterial mp3

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Study: NCT03062163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resveratrol lipoic Acid
Description: Transdermal patch loaded with resveratrol and lipoic acid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Transdermal patch loaded with normal saline
Study: NCT02040077

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer + Fluency

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer Only

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Study: NCT00216138

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 60 mg/m2 for 60 minutes, day 1 of each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 825 mg/m2 po bid, days 1-14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premedication
Description: Dexamethasone and antiemetic premedication
Study: NCT02279108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: One injection, 2.5 milligrams per patient, intradermal use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotope
Description: One injection, 20 MBq techntium99, intradermal use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isotope
Description: One injection, 20 MBq techntium99, intradermal use
Study: NCT02768831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Sealing the airway by holding CPAP of 20 cmH2O in the anesthesia circuit and slowly inflating the cuff until no air leak is heard with a stethoscope placed in the suprasternal notch.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tidal volume
Description: The ratio of the inspired to expired tidal volume will be determined using the following formula: (TVinspired - TV¬expired)/TVinspired. The peak inflating pressure (PIP) required to achieve the set TV will be noted. The air in the cuff will then be increased or decreased as needed to achieve a set delivered ratio of 0.9-1.0.
Study: NCT01128309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Reduction Intervention
Description: eight week group program, plus daily homework practice

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control intervention
Description: weekly group meetings for eight weeks, plus daily homework practice
Study: NCT05455008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remotely-delivered health coaching intervention
Description: Single-arm remotely-delivered health coaching intervention to increase physical activity and reduce sedentary behavior during pregnancy, consisting of 12 health coaching sessions.
Study: NCT03840343

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose
Description: Two MSC infusions of 2.5x10\^5 cells/kg at time zero and three months; single kidney, intra-arterial delivery
Study: NCT00574509

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 131Iodine-Anti-B1 Radioimmunotherapy
Description: Dosimetric dose of 450 mg unlabeled Anti-B1 followed by 35 mg Anti-B1 which has been trace labeled with 5mCi of 131I-Anti-B1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEAM
Description: Carmustine (B) also known as BCNU Etoposide (E) Cytarabine (A) also known as Ara-C and cytosine arabinoside Melphalan (M) also known as alkeran
Study: NCT00004984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parenteral Insulin
Description: Subcutaneous injections of recombinant human ultralente insulin in the morning and in the evening; the initial dose for each injection was 0.125 U per kilogram of body weight.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Close Observation
Description: Study visits every 6 months including an oral glucose tolerance test
Study: NCT03840343

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose
Description: Two MSC infusions of 5.0x10\^5 cells/kg at time zero and three months; single kidney, intra-arterial delivery
Study: NCT02593708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Study: NCT01762839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single-Dose IV Oritavancin Diphosphate
Description: Intravenous oritavancin was administered via 2 dedicated, peripheral venous lines, 1 in each arm. The infusion lasted approximately 3 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous placebo was administered via 2 dedicated, peripheral venous lines, 1 in each arm. The infusion lasted approximately 3 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Participants randomized to the open-label moxifloxacin treatment arm only received a 400-mg moxifloxacin tablet and did not receive a placebo infusion.
Study: NCT02593708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study: NCT01537055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levofloxacin-based sequential therapy
Description: levofloxacin-based sequential therapy for 10 days〔lansoprazole 30mg and amoxicillin 1g for the first 5 days, followed by lansoprazole 30mg, levofloxacin 250mg, and metronidazole 500mg for another 5 days (all given twice daily)〕

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levofloxacin-based triple therapy for 10 days
Description: lansoprazole 30mg and amoxicillin 1g, and levofloxacin 250mg for 10 days (all given twice daily)
Study: NCT02458547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Inhalation anesthesia with desflurane at age-adjusted MAC of 0.8\~1.0

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Total intravenous anesthesia with propofol target controlled infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Spinal anesthesia with 0.5% bupivacaine
Study: NCT02483130

Intervention type: DIETARY_SUPPLEMENT
Intervention: N-Acetylcysteine
Description: Participants will receive 2400mg of N-Acetylcysteine orally via 6 x 400mg capsules.
Study: NCT00500604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan/hydrochlorothiazide
Description: 150/12.5mg tablet and 300/12.5mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan/hydrochlorothiazide
Description: 80/12.5mg tablet and 160/12.5mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: 12.5 mg administered orally, once daily in the morning
Study: NCT02961049

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gingival displacement
Description: Gingival displacement with a gingival cord (#0, #00 or #000) with specific spatula.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Enamel and dentin etched
Description: Enamel and dentin etched with 35% phosphoric acid for 30 and 15 seconds, respectively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Enamel and dentin etched
Description: Enamel and dentin etched with 35% phosphoric acid for 30 and 15 seconds, respectively.
Study: NCT02483130

Intervention type: OTHER
Intervention: Placebo
Description: Participants will receive 2400mg of placebo orally via 6 x 400mg capsules.
Study: NCT00500604

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: 12.5 mg administered orally, once daily in the morning
Study: NCT01875042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: Transcutaneous electrical nerve stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TENS
Description: Sham Transcutaneous electrical nerve stimulation
Study: NCT03777124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: Subjects receive SHR-1210 intravenous every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Subjects receive Apatinib orally every day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Subjects receive Pemetrexed intravenous every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: subjects receive carboplatin intravenous every 3 weeks
Study: NCT03517995

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulforaphane Administration
Description: 1 capsule (10 mg Prostaphane) taken two times per day (2 capsules, 20 mg Prostaphane total).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: 1 capsule (placebo) taken two times per day (2 capsules total).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care Surgery
Description: The study will be conducted during the time from when participants are diagnosed with bladder cancer to when they undergo a surgical procedure for the treatment or removal of their bladder cancer. The surgical procedure is done as a part of their regular medical care.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Surgery
Description: The study will be conducted during the time from when participants are diagnosed with bladder cancer to when they undergo a surgical procedure for the treatment or removal of their bladder cancer. The surgical procedure is done as a part of their regular medical care.
Study: NCT04526470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Dose level -2: 200 mg PO once daily / Dose level -1: 200 mg PO once daily / Dose level 0: 250 mg PO once daily / Dose level 1: 300 mg PO once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Dose level -2: 60 mg/m2 IV on day 1, 8, and 15 / Dose level -1: 70 mg/m2 IV on day 1, 8, and 15 / Dose level 0: 70 mg/m2 IV on day 1, 8, and 15 / Dose level 1: 70 mg/m2 IV on day 1, 8, and 15
Study: NCT01694277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib
Description: 12 mg/kg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: 50 mg/day
Study: NCT01627444

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ear acupuncture
Description: Ear acupuncture based on Chinese Map: ShenMen, Anxiety 1 and 2, Tension, Muscular relaxation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ear acupuncture
Description: Ear acupuncture based on Chinese Map: ShenMen, Anxiety 1 and 2, Tension, Muscular relaxation.
Study: NCT02674425

Intervention type: DEVICE
Intervention: Dark Adaptometer

Intervention type: DEVICE
Intervention: Dark Adaptometer
Study: NCT02525939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dalcetrapib
Description: Cholesterol Ester Transfer Protein inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo tablets
Study: NCT02506686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: Meropenem i.v.
Study: NCT04287088

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: A shared decision making
Description: Based on prostate cancer risk calculation (age, usage of 5-ARI medication, baseline PSA, IMPROD bpMRI Likert, prostate volume) a shared decision making whether to perform prostate biopsies or not
Study: NCT04154319

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV Vaccination
Description: Mothers assigned to this arm participated in educational/behavior change sessions to promote HPV vaccination among their unvaccinated 9-12 year old daughters

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Eating
Description: Mothers and daughters assigned to this arm received education on healthy eating and how to appropriately interpret nutrition labels

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Eating
Description: Mothers and daughters assigned to this arm received education on healthy eating and how to appropriately interpret nutrition labels
Study: NCT02002468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test result sent by letter

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test result conveyed by general practitioners

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test result conveyed by general practitioners
Study: NCT00762996

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: contact lens
Study: NCT00514228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: * Starting dose: 37.5 mg 3 x 12.5 mg capsule~* Reduced dose: 25 mg 2 x 12.5 mg capsule
Study: NCT02723890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tyto Device
Study: NCT02944565

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV
Study: NCT03659058

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: silymarin
Description: silymarin 140 three times daily
Study: NCT03784898

Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw for future biomarker analysis
Description: Each participant was required to undergo blood draw for future genetic testing and biomarker analysis as mentioned in the informed consent form (ICF).
Study: NCT02320097

Intervention type: OTHER
Group type: OTHER
Intervention: Foot pressure measurement
Description: Description of the foot pressure measurement:~The subject stands on the platform, with the heels and buttocks touching a vertical plane and the head held freely. The subject then moves his/her head backwards so that it touches the vertical plane. Next, he/she turns the head to the right and then towards the left. Each of these positions is maintained for 2 minutes.~The platform's sensors measure the anteroposterior foot pressure distribution during the various acquisitions.
Study: NCT03847727

Intervention type: DRUG
Intervention: BR as Maintenance
Description: Patients of the study group who have achieved at least a partial response after 6 cycles of BR induction will receive additionally 4 cycles of BR every 3 months as maintenance therapy.
Study: NCT00868894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-104 medium concentration
Description: Topical ocular application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-104 high concentration
Description: Topical ocular application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical ocular application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.005% latanoprost
Description: Topical ocular application
Study: NCT03659058

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic Acid
Description: Ursodeoxycholic Acid 500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidants
Description: Beta Carotene - 6Mg Vitamin C - 200Mg Vitamin E - 50Mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine 0.6

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: FOLLOW UP
Description: follow up by abdominal ultrasound and fibroscan every 6 month for 1 year

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FOLLOW UP
Description: follow up by abdominal ultrasound and fibroscan every 6 month for 1 year